PHARMACY

Teva launches generic Lamictal XR in new strength

BY David Salazar
NORTH WALES, Penn. — Teva Pharmaceuticals on Wednesday announced the launch of its generic of Lamictal XR (lamotrigine) extended-release tablets in 250-mg dosage strength. 
 
The drug is indicated as an adjunctive therapy for patients older than 13 years of age with tonic-clonic seizure or partial-onset seizures with or without secondary generalization, and as monotherapy in patients older than 13 with partial onset seizures receiving treatment with a single AED. 
 
Teva has previously launched the drug in 25-, 50-, 100-, 200- and 300-mg dosage strengths. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Trump: ‘Drug industry getting away with murder’

BY Brian Berk

NEW YORK — President-elect Donald Trump took on health care and biotechnology companies during his Wednesday press conference.

"We have to get our drug industry coming back. The drug industry has been disastrous, they're leaving left and right. They supply our drugs but they don't make them here, to a large extent," Trump said in the press conference. "And the other thing we have to do is create new bidding procedures for the drug industry because they're getting away with murder.”

"We're the largest buyers of drugs but we don't bid properly," Trump added.

Trump’s comments led a host of pharmaceutical and biotech stocks to fall during Wednesday afternoon trade. The iShares Nasdaq Biotechnology exchange trade fund traded down nearly 3% for example.

Also Wednesday, the Generic Pharmaceutical Association responded to Trump’s comments. 

"We understand the President-Elect's concerns about drug prices. Patients and drug purchasers like the federal government, health systems, employers and others, rely on access to more affordable medicines," GPhA said. "Study after study demonstrates that generic medicines drive down drug costs through competition. Still, more can be done to increase competition and we look forward to working with the new Administration to reduce the backlog of generic drug applications at FDA, and on initiatives that bring more generic and biosimilar products to the market. Our recommendations to the Trump administration can be found here and our policy prescriptions to increase pharmaceutical competition are available at www.RxSolutions.us." 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Mayne Pharma launches Fabior, Sorilux

BY David Salazar
GREENVILLE, N.C. — Mayne Pharma on Wednesday announced the launch of Fabior (tazarotene, 0.1%) Foam and Sorilux (calcipotiene, 0.005%) Foam. Mayne Pharma acquired the products from GSK in August 2016, and they complement the company’s Doryx, the first branded product in its specialty brands division that it launched in 2015. 
 
Fabior is a foam product indicated to ttreat acne, and it part of the single active retinoid market, which sees 5 million prescriptions written annually. The company said the market for Fabior is larger than then the oral antibiotic acne market Mayne Pharma’s Doryx participates in. 
 
Sorilux is indicated for topical treatment of plaque psoriasis of the scalp and body, which affects as many as $6 million Americans annually and is part of the single active vitamin D market, which sees half a million prescriptions written every year.
 
“Both Fabior and Sorilux are a great strategic fit with the existing Doryx franchise and participate in attractive and growing markets. Both products are well differentiated with compelling clinical data that physicians and patients will appreciate,” Mayne Pharma CEO Scott Richards said. “The foam delivery platform has a well-established reputation with dermatologists due to ease of application, especially in hair-bearing areas and under clothing. With a focused and sustained marketing effort, we can further support the needs of patients and dermatologists and these products will become important treatment options for people with acne and plaque psoriasis.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?